Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 62
Summary
- Conditions
- HER2 Positive Breast Cancer
- Metastatic Breast Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 19 years and 125 years
- Gender
- Both males and females
Description
All the patients will be included in the final analysis, with a total of 15 patients to be enrolled. Treatment will occur until disease progression, unacceptable toxicity or patient withdrawal. Tumor measurement and evaluation are going to be performed at every 6 weeks for the first 3 months, then a...
All the patients will be included in the final analysis, with a total of 15 patients to be enrolled. Treatment will occur until disease progression, unacceptable toxicity or patient withdrawal. Tumor measurement and evaluation are going to be performed at every 6 weeks for the first 3 months, then at every 9 weeks till progression, and then follow-up evaluation at every 12 weeks thereafter end of study.
Tracking Information
- NCT #
- NCT03698383
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Kyong Hwa Park, MD, PhD Korean Cancer Study Group
Get Well Soon